For the year ending 2025-12-31, AKBA made $236,196K in revenue. -$5,345K in net income. Net profit margin of -2.26%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenues | 236,196 | |||
| Cost of product and other revenue | 39,462 | |||
| Amortization of intangible asset | 0 | |||
| Total cost of goods sold | 39,462 | |||
| Research and development | 62,359 | |||
| Selling, general and administrative | 107,480 | |||
| License | 3,396 | |||
| Restructuring | 0 | |||
| Total operating expenses | 173,235 | |||
| Income (loss) from operations | 23,499 | |||
| Interest expense | -24,179 | |||
| Other income | 58 | |||
| Change in fair value of warrant liability | 3,099 | |||
| Loss on extinguishment of debt | 0 | |||
| Loss on termination of lease | 0 | |||
| Loss before income taxes | -3,721 | |||
| Income tax expense | 1,624 | |||
| Net loss | -5,345 | |||
| Comprehensive loss | -5,345 | |||
| Basic EPS | -0.02 | |||
| Diluted EPS | -0.02 | |||
| Basic Average Shares | 257,157,782 | |||
| Diluted Average Shares | 257,157,782 | |||
Akebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. (AKBA)